Ranitidine HCI(U-rantac) is a highly effective, rapidly acting histamine H2-receptor antagonist. It inhibit basal and stimulated secretion of gastric acid, reducing both the volume, and the acid pepsin content of the secretion. Now, It has been widely used for treatment of the peptic ulcer. We has investigated the effect of Ranitidine HCI in the Bootie ulcer and stomach cancer in 62 patients who had been admitted to the Department of General Surgery, Chungnam National University Hospital from Jan. 1987 to Apr. 1987.
The following results were obtained:
1. The prevalent age in duodenal ulcer was fourth decade, gastric ulcer, fifth decade, and stomach cancer, sixth decade, respectively.
2. The male to female ratio in duodenal ulcer was 2.8 : 1, gastric ulcer, 2 : 1, and stomach cancer, 1 : 1.
3. After intramuscular injection of Ranitidine HCI in duodenal ulcer, volume of gastric secretion was decreased in 31ml/hr (36%) in male and 20ml/hr (33%) in female, and gastric acidify was decreased in 3.5mEq/hr (54.4%) and 2.0mEq/hr (48.8%). respectively. In gastric ulcer, the volume of gastric secretion was decreased in 14ml/hr (21.9%) in male and 4ml/hr (7.7%) in female, and the gastric acidity was decreased in 0.9mEq/hr (39.0%) and 0.6mq/hr(23.1%), respectively. In stomach cancer, the volume of the gastric secretion was decreased in 17ml/hr(28.8%) in male and 15ml/hr (25.9%) in female, and the gastric acidity was decreased in 0.5mEq/hr (15.6%) and 0.6mEq/hr (19.4%), respectively.
|